Why carry out this study?

- Given the renal site of action of sodium glucose co-transporter 2 (SGLT2) inhibitors and their mild diuretic mode of action, there is potential concern about their effects on electrolyte balance, including potassium.
- This pooled analysis aimed to determine whether or not dapagliflozin 10 mg affected the risk of potassium imbalance in patients with type 2 diabetes mellitus (T2DM).

What was learned from the study?

- Dapagliflozin did not increase the incidence of serum potassium abnormalities of ≥5.5 or ≤2.5 mmol/L, including in those patients at greater risk of potassium imbalance.
- Dapagliflozin is not associated with an increased risk of hyperkalemia or severe hypokalemia in patients with T2DM.

This summary slide represents the opinions of the authors. This study was supported by Bristol-Myers Squibb and AstraZeneca. Editorial assistance in the preparation of this manuscript was provided by Helen Brereton and Julian Martins of inScience Communications, Springer Healthcare Ltd, London, UK, and was funded by AstraZeneca. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online.